Skip Navigation

Annals of Oncology 2006 17(Supplement 8):viii43-viii46; doi:10.1093/annonc/mdl987
This Article
Right arrow Full Text (PDF)
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Lassarat, S.
Right arrow Articles by Jootar, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lassarat, S.
Right arrow Articles by Jootar, S.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 European Society for Medical Oncology

symposium article

Ongoing challenges of a global international patient assistance program

S. Lassarat1,* and S. Jootar2

1 Global Patient Access, Novartis Oncology; 2 Ramathibodi Hospital, Mahidol University, Thailand

* Correspondence to: S. Lassarat, Novartis Pharma AG, Klybeckstrasse 141, 4057 Basel, Switzerland. Tel: +41 61 696 24 59; Fax: +41 61 696 32 77; E-mail: stephanie.lassarat{at}novartis.com

The Glivec International Patient Assistance Program (GIPAPTM) that is supported by Novartis Oncology provides Glivec (imatinib), an innovative oral therapy for chronic myelogenous leukemia and gastrointestinal stromal tumours, at no cost to patients in developing countries who could otherwise not afford treatment. Using a novel direct-to-patient approach this program is currently successfully providing Glivec to underserved patients in 81 countries. A number of challenges were faced in the implementation of this program in countries where cancer is not a priority, and where the healthcare and other infrastructure can be very limited. By working within the existing healthcare system of each country, and with any national cancer control programme that may be in place, through careful selection of qualified institutions and physicians, while maintaining a global approach to ensure consistency and quality, GIPAP has become an efficient and sustainable access program. Novartis has made a long-term commitment to GIPAP, and is currently exploring new patient access programs for other drugs.

Key words: Glivec, chronic myelogenous leukemia, gastrointestinal stromal tumours, patient access, developing countries


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Ann OncolHome page
R. Capdeville, T. Krahnke, A. Hatfield, J. M. Ford, I. Van Hoomissen, and I. Gathmann
Report of an international expanded access program of imatinib in adults with Philadelphia chromosome positive leukemias
Ann. Onc., July 1, 2008; 19(7): 1320 - 1326.
[Abstract] [Full Text] [PDF]


Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.